<DOC>
	<DOC>NCT00412984</DOC>
	<brief_summary>The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.</brief_summary>
	<brief_title>Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke: Age ≥ 75, previous stroke transient ischemic attack (TIA) or Systemic Embolism (SE) Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40% Diabetes mellitus or hypertension requiring pharmacological treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>